Pfizer brings frequent heartburn relief OTC with new Nexium® 24HR

PfizerPfizer Inc. (NYSE: PFE) has announced the introduction in the U.S. of over-the-counter (OTC) Nexium®24HR, making The Purple Pill® available for the treatment of frequent heartburn (two or more days a week) in adults (18 years and older). Heartburn affects more than 60 million men and women in the United States at least once a month with 15 million Americans suffering from it daily.(1)

Pfizer acquired exclusive global OTC rights to NEXIUM®, one of the largest selling prescription brands in the U.S., from AstraZeneca in August 2012. Nexium 24HR was approved by the Food and Drug Administration on March 28, and received three year market exclusivity. Switching medicines from prescription to non-prescription status improves consumer access to affordable healthcare options, empowers people to take charge of their health, and is an important strategy for Pfizer. The launch of Nexium 24HR makes Pfizer a leading player in all four of the largest OTC categories - pain management, dietary supplements, respiratory and, now, digestive.

"The addition of Nexium 24HR to our portfolio enhances our ability to help consumers better manage their health," said Paul Sturman, President and General Manager, Pfizer Consumer Healthcare. "Nexium 24HR creates a new option for treating frequent heartburn with the confidence of a brand that consumers and healthcare providers know and trust. The OTC availability of Nexium 24HR in the U.S. marks the first step in our efforts to build a strong, global position in digestive health with this powerful brand."

Nexium 24HR has been available in the U.S. for preorder at Nexium24HR.com since April 15, 2014, and, within 72 hours, Nexium 24HR will be available nationwide at most retailer outlets.

"Switching a brand with this kind of loyalty and equity is a tremendous business opportunity, and we have a critical responsibility to our partners, to our retail customers, to healthcare providers and most importantly, to consumers," said T.J. Higgins, North American President, Pfizer Consumer Healthcare. "Nexium 24HR protects people from frequent heartburn, and also from the fear and hesitation that heartburn causes."

Nexium 24HR works differently than other OTC medications for heartburn such as antacids and histamine blockers. Specifically, Nexium 24HR is a proton pump inhibitor (PPI), which means it stops acid production at the source, by blocking the pumps that release acid into the stomach. In fact, PPIs like Nexium 24HR are the only FDA-approved medications for over-the-counter treatment of frequent heartburn.

"I, along with many of my colleagues, have come to trust The Purple Pill® as the number one prescribed acid blocker brand," said David A. Johnson, MD, MACG, FASGE, Professor of Medicine and Chief of Gastroenterology Eastern VA Medical School Norfolk VA. "The availability of Nexium 24HR represents an important development in access to the medication at a time when people are in need of a short term course of therapy for effective self-care solutions. And with 15 million Americans suffering from heartburn daily(1), making NEXIUM available without prescription helps to fill a crucially important unmet need."

Nexium 24HR is to be used once a day (every 24 hours), every day for 14 days and may take 1-4 days for full effect. The 14-day course can be repeated every 4 months. People should not take more than 1 capsule of Nexium 24HR a day, unless directed by a doctor.

About Nexium® 24HR
Nexium® 24HR brings NEXIUM®, the #1 doctor-prescribed acid-reducer brand, over-the-counter to treat frequent heartburn. The active ingredient in Nexium® 24HR is esomeprazole 20 mg, which is a part of a group of medications called proton pump inhibitors or PPIs. Nexium 24HR works by blocking acid at the source, giving 24 hours of protection from frequent heartburn when used as directed. Nexium 24HR represents an important development in increased access to The Purple Pill® by giving people a new way to access a trusted, effective product. If you have questions about whether Nexium 24HR is right for you, speak with your healthcare provider prior to taking the product.

Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

1. Smoking and Your Digestive System. 1999. National Digestive Diseases Information Clearinghouse. NIH Publication No.99-949.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Syntropy to unlock the value of scientific data in…

Merck, a leading science and technology company, and software company Palantir Technologies, today announced their intent to form a joint venture under the brand name Syn...